The European Medicines Agency (EMA) published an updated frequently asked questions (FAQ) document on April 9, 2026, aimed at assisting sponsors and researchers in navigating the Clinical Trial Information System (CTIS) for submitting clinical trial applications and managing ongoing trials. The document, released by EMA's Clinical Trials and Human Medicines Division, provides practical guidance on common issues encountered by pharmaceutical companies, contract research organizations, and academic institutions conducting clinical trials in the EU.
The updated FAQ follows the agency's publication of a new training module on April 7, 2026, which covered the notification process for substantial modifications to ongoing trials. Both documents support the implementation of the Clinical Trials Regulation (EU) No 536/2014, which became applicable on January 31, 2022, introducing a centralized EU portal and database (CTIS) for clinical trial applications, replacing national submission systems.
Document Type and Status The FAQ is a guidance document and is not legally binding, but it provides clarifications on regulatory expectations and procedural steps. It addresses topics such as user account management, submission workflows, and data entry requirements, aiming to reduce errors and streamline the application process.
Policy Orientations and Trade-offs The FAQ reflects a trade-off between standardizing procedures to enhance regulatory efficiency and maintaining flexibility for sponsors to adapt to specific trial designs. By clarifying common ambiguities, the EMA seeks to improve data quality and comparability across studies, which can facilitate faster regulatory decisions. However, the detailed guidance may impose additional administrative burdens on sponsors, particularly smaller companies and academic researchers with limited resources.
Impact on Stakeholders - Pharmaceutical companies: Benefit from clearer submission pathways, potentially reducing delays in trial approvals. However, they must invest time in understanding and implementing the updated guidance. - Contract research organizations (CROs): Face similar benefits and costs, with the need to update internal procedures and train staff. - Academic researchers: May struggle with the complexity of CTIS and the additional administrative load, potentially discouraging smaller academic trials. - Patient advocacy groups: Indirectly benefit from more efficient trial oversight, which can accelerate access to new treatments.
Expected Institutional Follow-up The EMA is expected to continue updating the FAQ and training materials based on user feedback and emerging issues. The agency may also conduct stakeholder workshops to address persistent challenges, as part of its ongoing commitment to support the Clinical Trials Regulation.
← Atlas › News › EU affairs & Institutions